Insider Trades: 5 ASX 200 directors bought and sold these stocks last week
Directors bought into weakness at Integral Diagnostics, Ramelius and Liontown, while the managing directors of Abacus and Data#3 sold.
Source: Shutterstock
Mentioned
Welcome back to the Insider Trades series – a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The below trades have all taken place between 30 October and 6 November. Directors have up to 5 business days to notify the ASX of their trades.
Last week was an eventful one for markets, with the ASX 200 posting its best day since April 2025 on 5 November, but director trading was quieter. Three directors bought, led by Integral Diagnostics’ Andrew Fay, who added shares after the stock hit a 52-week low. Two managing directors sold, including Abacus Group’s Steven Sewell, who offloaded $830,000 worth of shares.
Top ASX 200 insider buys
Code | Company | Date | Director | Type | Price | Value |
|---|---|---|---|---|---|---|
IDX | Integral Diagnostics | 03/11/26 | Buy | $1.73 | $103,650 | |
RMS | Ramelius Resources | 04/11/26 | Buy | $3.41 | $51,138 | |
LTR | Liontown | 04/11/26 | Buy | $0.62 | $29,355 |
Integral Diagnostics non-exec director buys the dip
Integral Diagnostics (IDX) has spent most of this year trading in-line with the broader S&P/ASX 200 Healthcare sector, tracking its first-half decline and second-half recovery, though this relationship decoupled in late September, followed by a ~15% one-day selloff on 29 October after the company’s AGM guided to weaker-than-expected growth.
"Revenue growth in the first quarter was softer than we expected, driven by labour shortages. We expect full year FY27 revenue growth to be between 4.0% to 6.0%," noted CEO Jason Martinez.
Integral Diagnostics (red) vs. S&P/ASX 200 Healthcare index (blue) year-to-date | Source: TradingView
Bell Potter cut its FY27 earnings forecast by 18% in a note after the AGM and also cut its price target to $2.70 from $3.15, while keeping a Buy rating.
Non-Executive Director Andrew Fay, on the board since July 2022, bought into the sell-off on 3 November, buying 60,000 shares at $1.73 each through his wife’s holding. The purchase lifted his total interest 70.6% from 85,000 to 145,000 shares and was his first change in interest since November 2023.
Liontown director buys the dip
Liontown (LTR) shares have tanked 56% year-to-date, and down 73% since June as lithium prices have more than halved since May highs and the company ramps up underground mining at Kathleen Valley.
Liontown suffered a 15% selloff on 1 October, the day after it announced a positive Final Investment Decision to expand Kathleen Valley's production to around 780ktpa from FY30 (previously ~500ktpa). Bell Potter called the move highly capital efficient but cut its target (from $1.90 to $1.70) on the later production timing.
The expansion lifts spodumene concentrate capacity to about 780ktpa from FY30, up from about 500ktpa
Expansion capex of $389m will be spent over FY27–29, funded from cash of $561m at 30 June and operating cash flow
FY27 capex guidance was lifted to $435–495m from $320–370m, with production and unit cost guidance reiterated
Targeted unit costs are $840–920/t (US$610–670/t) at expanded rates, with annual sustaining capex of $90–100m
Non-Executive Director Jennifer Morris, the company’s lead independent director and on the board since November 2021, bought 47,285 shares at $0.62 each on 4 November. The purchase lifted her holding 18.7% to 300,000 shares and was her first on-market buy since picking up 70,000 shares at $0.56 in December 2024.
Top ASX 200 insider sells
Code | Company | Date | Director | Type | Price | Value |
|---|---|---|---|---|---|---|
ABG | Abacus Group | 02/11/26 | Sell | $0.83 | $830,000 | |
DTL | Data#3 | 11/05/2026 | Sell | $15.00 | $150,000 |
Abacus MD sells after distribution cut
Abacus Group (ABG), which owns and manages office towers and retail property, is down 24% year-to-date, more than double the 11% decline in the S&P/ASX 200 Real Estate index.
Part of the sell-off has weighed the whole sector, as property stocks are sensitive to interest rates, and they fell as Australian bond yields climbed until late September.
Year-to-date ABG share price vs. Australian 10 year bond yield (Source: TradingView)
Abacus also reported weak operating earnings and in late August cut its forecast payout to investors by 21% to 6.7 cents per security. On 18 September it agreed to sell its remaining 19.6% stake in Storage King for $284.8 million to pay down debt, at a discount, which also ends the fees Abacus earned for running the self-storage business.
Some of that damage has started to reverse, with the Aussie 10-year down 45 bps since 29 September to 4.99% and Abacus shares up around 12% since late October.
Managing Director Steven Sewell is selling at an interesting juncture, with bond yields easing and property stocks recovering, but Abacus’s own problems unresolved since the payout cut and the Storage King sale. Sewell, in the role since April 2018, sold 1 million securities on-market at $0.83 each on 2 November, cutting his holding by about a third to 2.17 million securities. In September he received 788,807 Abacus securities as part of his pay after meeting the conditions of the company’s incentive plan.
Data#3 CEO trims holding after 70% rally YTD
Data#3 (DTL) shares are up a massive 70% year-to-date, supercharged by two profit upgrades in October.
1 Oct: First-half FY27 profit before tax (PBT) up at least 40%
28 Oct: First half FY27 PBT up between 55-70%
UBS kept its Neutral rating and lifted its target to $15.50 from $11.00 in a 28 October note, saying the share price already reflects most of the good news.
Managing Director and CEO Brad Colledge, in the role since March 2024, sold 10,000 shares at $15.00 each on 5 November, about 2% of his holding. He still holds about 464,000 shares.
